We've found
12,064 Hematology
clinical trials
Cardiology / Vascular Diseases, Hematology Clinical Trial
VCRC Tissue Repository
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Cardiology / Vascular Diseases, Hematology Clinical Trial
Clinical Transcriptomics in Systemic Vasculitis (CUTIS)
Status: Enrolling,
Phase
Updated: 4/10/2018
Click here to add this to my saved trials
Hematology, Oncology, Other Clinical Trial
HA-1 T TCR T Cell Immunotherapy for the Treating of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Chronic Myelogenous Leukemia Clinical Trial
Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Chronic Myelogenous Leukemia Clinical Trial
Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Multiple Myeloma Clinical Trial
Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Multiple Myeloma Clinical Trial
Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Multiple Myeloma Clinical Trial
A Phase 1/2a Dose-Finding Study of PT-112 in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Multiple Myeloma Clinical Trial
A Phase 1/2a Dose-Finding Study of PT-112 in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Multiple Myeloma Clinical Trial
Dose-Escalation Study of BFCR4350A in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology, Other Clinical Trial
Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Management and Outcomes of Anti-thrombotic Medication Use in Thrombocytopenia
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Hematological Malignancies Clinical Trial
Dose Escalation Study of JNJ-64007957, a Humanized BCMA CD3 DuoBody® Antibody, in Participants With Relapsed or Refractory Multiple Myeloma
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Hypereosinophilic Syndrome Clinical Trial
Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Hypereosinophilic Syndrome Clinical Trial
Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
A Phase 1 Study to Evaluate H3B-8800 in Participants With Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
A Phase 1 Study to Evaluate H3B-8800 in Participants With Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
A Phase 1 Study to Evaluate H3B-8800 in Participants With Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
DS-3201b for Acute Myelogenous Leukemia (AML) or Acute Lymphocytic Leukemia (ALL)
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
DS-3201b for Acute Myelogenous Leukemia (AML) or Acute Lymphocytic Leukemia (ALL)
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Hemophilia A Clinical Trial
A Gene Transfer Study for Hemophilia A
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Hemophilia A Clinical Trial
A Gene Transfer Study for Hemophilia A
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Single Agent Decitabine in TP53 Mutated Relapsed/Refractory Acute Myeloid Leukemia
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Acute Myeloid Leukemia Clinical Trial
A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Acute Myeloid Leukemia Clinical Trial
A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Acute Myeloid Leukemia Clinical Trial
A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Acute Myeloid Leukemia Clinical Trial
A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Acute Myeloid Leukemia Clinical Trial
A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Acute Myeloid Leukemia Clinical Trial
A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Acute Myeloid Leukemia Clinical Trial
A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Acute Myeloid Leukemia Clinical Trial
A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Acute Myeloid Leukemia Clinical Trial
A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Acute Myeloid Leukemia Clinical Trial
A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Acute Myelogenous Leukemia Clinical Trial
DC/AML Fusion Cell Vaccine vs Observation in Patients Who Achieve a Chemotherapy-induced Remission
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Safety, PK, PD, and Antitumor Activity of SNS-062 (Vecabrutinib) in B Lymphoid Cancers
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Nivolumab With Epstein Barr Virus Specific T Cells (EBVSTS), Relapsed/Refractory EBV Positive Lymphoma (PREVALE)
Status: Enrolling,
Phase
I
Updated: 1/18/2018
Click here to add this to my saved trials
Acute Myeloid Leukemia Clinical Trial
Study of AMV564 in Patients With AML
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Acute Myeloid Leukemia Clinical Trial
Study of AMV564 in Patients With AML
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Acute Myeloid Leukemia Clinical Trial
Onvansertib in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia (AML).
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Acute Myeloid Leukemia Clinical Trial
Onvansertib in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia (AML).
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
A Safety and Efficacy Study to Evaluate Luspatercept in Subjects With Myeloproliferative Neoplasm-associated Myelofibrosis Who Have Anemia With and Without Red Blood Cell-transfusion Dependence
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Multiple Myeloma Clinical Trial
A Study of JNJ-63723283, an Anti-programmed Death-1 Monoclonal Antibody, Administered in Combination With Daratumumab, Compared With Daratumumab Alone in Participants With Relapsed or Refractory Multiple Myeloma
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Multiple Myeloma Clinical Trial
Monoclonal Antibody-Based Sequential Therapy for Deep Remission in Multiple Myeloma
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Multiple Myeloma Clinical Trial
BCMA Targeted CAR T Cells With or Without Lenalidomide for the Treatment of Multiple Myeloma
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Graft Versus Host Disease Clinical Trial
Detection of Graft Versus Host Disease With [18F]F-AraG
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology Clinical Trial
Pre-myeloid Cancer and Bone Marrow Failure Clinic Study
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Hemophilia A Clinical Trial
Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Hemophilia A Clinical Trial
Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Chronic Phase Chronic Myeloid Leukemia Clinical Trial
Determining Change in Cardiovascular and Metabolic Risks in Patients With Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Chronic Phase Chronic Myeloid Leukemia Clinical Trial
Determining Change in Cardiovascular and Metabolic Risks in Patients With Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Chronic Phase Chronic Myeloid Leukemia Clinical Trial
Determining Change in Cardiovascular and Metabolic Risks in Patients With Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Chronic Phase Chronic Myeloid Leukemia Clinical Trial
Determining Change in Cardiovascular and Metabolic Risks in Patients With Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Chronic Phase Chronic Myeloid Leukemia Clinical Trial
Determining Change in Cardiovascular and Metabolic Risks in Patients With Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Chronic Phase Chronic Myeloid Leukemia Clinical Trial
Determining Change in Cardiovascular and Metabolic Risks in Patients With Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Chronic Phase Chronic Myeloid Leukemia Clinical Trial
Determining Change in Cardiovascular and Metabolic Risks in Patients With Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Beta-Thalassemia Clinical Trial
A Study Evaluating the Efficacy and Safety of the LentiGlobin® BB305 Drug Product in Subjects With Transfusion-Dependent β-Thalassemia, Who Have a β0/β0 Genotype
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Study of IMGN632 in Patients With Relapse/Refractory AML, BPDCN, ALL, Other CD123+ Hem Malignancies
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Cardiology / Vascular Diseases, Hematology, Immunology / Infectious Diseases, Nephrology / Urology Clinical Trial
Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using the MATE Score
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Cardiology / Vascular Diseases, Hematology, Immunology / Infectious Diseases, Nephrology / Urology Clinical Trial
Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using the MATE Score
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Cardiology / Vascular Diseases, Hematology, Immunology / Infectious Diseases, Nephrology / Urology Clinical Trial
Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using the MATE Score
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
We've found
12,064 Hematology
clinical trials
Cardiology / Vascular Diseases, Hematology Clinical Trial
Updated: 12/31/1969
VCRC Tissue Repository
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Cardiology / Vascular Diseases, Hematology Clinical Trial
Updated: 4/10/2018
Clinical Transcriptomics in Systemic Vasculitis (CUTIS)
Status: Enrolling,
Phase
Updated: 4/10/2018
Click here to add this to my saved trials
Hematology, Oncology, Other Clinical Trial
Updated: 12/31/1969
HA-1 T TCR T Cell Immunotherapy for the Treating of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Chronic Myelogenous Leukemia Clinical Trial
Updated: 12/31/1969
Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Chronic Myelogenous Leukemia Clinical Trial
Updated: 12/31/1969
Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Multiple Myeloma Clinical Trial
Updated: 12/31/1969
Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Multiple Myeloma Clinical Trial
Updated: 12/31/1969
Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Multiple Myeloma Clinical Trial
Updated: 12/31/1969
A Phase 1/2a Dose-Finding Study of PT-112 in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Multiple Myeloma Clinical Trial
Updated: 12/31/1969
A Phase 1/2a Dose-Finding Study of PT-112 in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Multiple Myeloma Clinical Trial
Updated: 12/31/1969
Dose-Escalation Study of BFCR4350A in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology, Other Clinical Trial
Updated: 12/31/1969
Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Management and Outcomes of Anti-thrombotic Medication Use in Thrombocytopenia
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Hematological Malignancies Clinical Trial
Updated: 12/31/1969
Dose Escalation Study of JNJ-64007957, a Humanized BCMA CD3 DuoBody® Antibody, in Participants With Relapsed or Refractory Multiple Myeloma
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Hypereosinophilic Syndrome Clinical Trial
Updated: 12/31/1969
Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Hypereosinophilic Syndrome Clinical Trial
Updated: 12/31/1969
Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Updated: 12/31/1969
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Updated: 12/31/1969
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Updated: 12/31/1969
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Updated: 12/31/1969
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Updated: 12/31/1969
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Updated: 12/31/1969
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Updated: 12/31/1969
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Updated: 12/31/1969
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Updated: 12/31/1969
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Updated: 12/31/1969
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Updated: 12/31/1969
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Updated: 12/31/1969
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Updated: 12/31/1969
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Updated: 12/31/1969
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Updated: 12/31/1969
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Updated: 12/31/1969
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Updated: 12/31/1969
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Updated: 12/31/1969
A Phase 1 Study to Evaluate H3B-8800 in Participants With Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Updated: 12/31/1969
A Phase 1 Study to Evaluate H3B-8800 in Participants With Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Updated: 12/31/1969
A Phase 1 Study to Evaluate H3B-8800 in Participants With Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Updated: 12/31/1969
DS-3201b for Acute Myelogenous Leukemia (AML) or Acute Lymphocytic Leukemia (ALL)
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Updated: 12/31/1969
DS-3201b for Acute Myelogenous Leukemia (AML) or Acute Lymphocytic Leukemia (ALL)
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Hemophilia A Clinical Trial
Updated: 12/31/1969
A Gene Transfer Study for Hemophilia A
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Hemophilia A Clinical Trial
Updated: 12/31/1969
A Gene Transfer Study for Hemophilia A
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Single Agent Decitabine in TP53 Mutated Relapsed/Refractory Acute Myeloid Leukemia
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Acute Myeloid Leukemia Clinical Trial
Updated: 12/31/1969
A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Acute Myeloid Leukemia Clinical Trial
Updated: 12/31/1969
A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Acute Myeloid Leukemia Clinical Trial
Updated: 12/31/1969
A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Acute Myeloid Leukemia Clinical Trial
Updated: 12/31/1969
A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Acute Myeloid Leukemia Clinical Trial
Updated: 12/31/1969
A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Acute Myeloid Leukemia Clinical Trial
Updated: 12/31/1969
A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Acute Myeloid Leukemia Clinical Trial
Updated: 12/31/1969
A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Acute Myeloid Leukemia Clinical Trial
Updated: 12/31/1969
A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Acute Myeloid Leukemia Clinical Trial
Updated: 12/31/1969
A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Acute Myeloid Leukemia Clinical Trial
Updated: 12/31/1969
A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Acute Myelogenous Leukemia Clinical Trial
Updated: 12/31/1969
DC/AML Fusion Cell Vaccine vs Observation in Patients Who Achieve a Chemotherapy-induced Remission
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Updated: 12/31/1969
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Updated: 12/31/1969
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Updated: 12/31/1969
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Updated: 12/31/1969
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Updated: 12/31/1969
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Safety, PK, PD, and Antitumor Activity of SNS-062 (Vecabrutinib) in B Lymphoid Cancers
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Updated: 1/18/2018
Nivolumab With Epstein Barr Virus Specific T Cells (EBVSTS), Relapsed/Refractory EBV Positive Lymphoma (PREVALE)
Status: Enrolling,
Phase
I
Updated: 1/18/2018
Click here to add this to my saved trials
Acute Myeloid Leukemia Clinical Trial
Updated: 12/31/1969
Study of AMV564 in Patients With AML
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Acute Myeloid Leukemia Clinical Trial
Updated: 12/31/1969
Study of AMV564 in Patients With AML
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Acute Myeloid Leukemia Clinical Trial
Updated: 12/31/1969
Onvansertib in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia (AML).
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Acute Myeloid Leukemia Clinical Trial
Updated: 12/31/1969
Onvansertib in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia (AML).
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Updated: 12/31/1969
A Safety and Efficacy Study to Evaluate Luspatercept in Subjects With Myeloproliferative Neoplasm-associated Myelofibrosis Who Have Anemia With and Without Red Blood Cell-transfusion Dependence
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Multiple Myeloma Clinical Trial
Updated: 12/31/1969
A Study of JNJ-63723283, an Anti-programmed Death-1 Monoclonal Antibody, Administered in Combination With Daratumumab, Compared With Daratumumab Alone in Participants With Relapsed or Refractory Multiple Myeloma
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Multiple Myeloma Clinical Trial
Updated: 12/31/1969
Monoclonal Antibody-Based Sequential Therapy for Deep Remission in Multiple Myeloma
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Updated: 12/31/1969
A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Updated: 12/31/1969
A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Multiple Myeloma Clinical Trial
Updated: 12/31/1969
BCMA Targeted CAR T Cells With or Without Lenalidomide for the Treatment of Multiple Myeloma
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Graft Versus Host Disease Clinical Trial
Updated: 12/31/1969
Detection of Graft Versus Host Disease With [18F]F-AraG
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology Clinical Trial
Updated: 12/31/1969
Pre-myeloid Cancer and Bone Marrow Failure Clinic Study
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Hemophilia A Clinical Trial
Updated: 12/31/1969
Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Hemophilia A Clinical Trial
Updated: 12/31/1969
Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Chronic Phase Chronic Myeloid Leukemia Clinical Trial
Updated: 12/31/1969
Determining Change in Cardiovascular and Metabolic Risks in Patients With Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Chronic Phase Chronic Myeloid Leukemia Clinical Trial
Updated: 12/31/1969
Determining Change in Cardiovascular and Metabolic Risks in Patients With Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Chronic Phase Chronic Myeloid Leukemia Clinical Trial
Updated: 12/31/1969
Determining Change in Cardiovascular and Metabolic Risks in Patients With Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Chronic Phase Chronic Myeloid Leukemia Clinical Trial
Updated: 12/31/1969
Determining Change in Cardiovascular and Metabolic Risks in Patients With Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Chronic Phase Chronic Myeloid Leukemia Clinical Trial
Updated: 12/31/1969
Determining Change in Cardiovascular and Metabolic Risks in Patients With Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Chronic Phase Chronic Myeloid Leukemia Clinical Trial
Updated: 12/31/1969
Determining Change in Cardiovascular and Metabolic Risks in Patients With Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Chronic Phase Chronic Myeloid Leukemia Clinical Trial
Updated: 12/31/1969
Determining Change in Cardiovascular and Metabolic Risks in Patients With Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Beta-Thalassemia Clinical Trial
Updated: 12/31/1969
A Study Evaluating the Efficacy and Safety of the LentiGlobin® BB305 Drug Product in Subjects With Transfusion-Dependent β-Thalassemia, Who Have a β0/β0 Genotype
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Study of IMGN632 in Patients With Relapse/Refractory AML, BPDCN, ALL, Other CD123+ Hem Malignancies
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Cardiology / Vascular Diseases, Hematology, Immunology / Infectious Diseases, Nephrology / Urology Clinical Trial
Updated: 12/31/1969
Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using the MATE Score
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Cardiology / Vascular Diseases, Hematology, Immunology / Infectious Diseases, Nephrology / Urology Clinical Trial
Updated: 12/31/1969
Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using the MATE Score
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Cardiology / Vascular Diseases, Hematology, Immunology / Infectious Diseases, Nephrology / Urology Clinical Trial
Updated: 12/31/1969
Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using the MATE Score
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials